cantharidin topical (Rx)

Brand and Other Names:Ycanth

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

topical solution

  • 0.7% (7mg/mL)
  • Each sealed glass ampule contains ~0.45mL
  • Break tool packaged as 2 units/carton of applicators

Molluscum Contagiosum

Indicated for topical treatment of molluscum contagiosum

Apply topically to cover each lesion by clinician q3weeks PRN; not to exceed 2 cantharidin applicators during a single session

See Administration

Dosage Forms & Strengths

topical solution

  • 0.7% (7mg/mL)
  • Each sealed glass ampule contains ~0.45mL
  • Break tool packaged as 2 units/carton of applicators

Molluscum Contagiosum

Indicated for topical treatment of molluscum contagiosum in patients aged ≥2 years

<2 years: Safety and efficacy not established

≥2 years: Apply topically to cover each lesion by clinician q3weeks PRN; not to exceed 2 cantharidin applicators during a single session

See Administration

Next:

Adverse Effects

>10%

Mild

  • Vesicles (60%)
  • Pruritus (47%)
  • Pain (41%)
  • Scab (39%)
  • Discoloration (28%)
  • Erythema (24%)
  • Dryness (19%)

Moderate

  • Vesicles (32%)
  • Erythema (21%)
  • Pain (20%)

1-10%

Mild

  • Edema (7%)
  • Erosion (6%)

Moderate

  • Scab (9%)
  • Pruritus (8%)
  • Discoloration (4%)
  • Edema (3%)
  • Dryness (2%)
  • Erosion (1%)
  • Contact dermatitis (1%)

Severe

  • Vesicles (4%)
  • Pain (2%)
  • Pruritus (1%)

<1%

Severe

  • Application site erythema
  • Application site discoloration
Previous
Next:

Warnings

Contraindications

None

Cautions

Toxicities associated with inappropriate administration

  • Life threatening or fatal toxicities can occur if administered orally
  • Avoid contact with treatment area, including oral contact, after treatment
  • Oral ingestion may result in renal failure, blistering and severe damage to gastrointestinal tract, coagulopathy, seizures, and flaccid paralysis
  • Ocular toxicity can occur if cantharidin comes in contact with eyes; if this occurs, flush eyes with water for at least 15 minutes
  • Contact with eyes can result in corneal necrosis, ocular perforation, and deep ocular injuries
  • Advise patients and/or caregivers to avoid oral and eye contact, and to avoid touching lesions after treatment; seek medical attention immediately if accidently ingested

Local skin reactions

  • Application site reactions reported, including vesiculation, pruritus, pain, discoloration, and erythema
  • Avoid application near eyes and mucosal tissue, and to healthy skin
  • Immediately remove solution by wiping with cotton swab or gauze if contact with unintended surface or healthy skin occurs
  • Avoid other topical products (eg, creams, lotions, sunscreen) on treated areas until 24 hr after treatment or until washing
  • Application of other topical products could spread cantharidin and cause blistering or other adverse reactions to healthy skin
  • If severe blistering, severe pain, or other severe adverse reactions occur, remove cantharidin before recommended 24 hr treatment period by washing with soap and water

Flammability

  • Solution is flammable, even after drying
  • Avoid fire, flame, or smoking near lesion(s) during treatment and after application until removed
Previous
Next:

Pregnancy & Lactation

Pregnancy

There are no available data with use in pregnant females to evaluate for drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes

Animal reproduction studies were not conducted

Systemic exposure following topical cantharidin administration is low; maternal use not expected to result in fetal exposure to the drug

Lactation

Avoid application to areas with increased risk for potential ingestion by or ocular exposure to breastfeeding child

There are no data on presence of cantharidin in either human or animal milk, or effects on breastfed infants, or on milk production

Breastfeeding is not expected to result in cantharidin exposure to child owing to low systemic absorption following topical administration

Consider developmental and health benefits of breastfeeding along with the clinical need for cantharidin and any potential adverse effects on breastfeeding children from cantharidin or from the underlying maternal condition

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Mechanism of action is unknown in the treatment of molluscum contagiosum

Cantharidin is absorbed by lipids in the membrane of epidermal keratinocytes, where it activates the release of neutral serine protease enzymes

These enzymes subsequently break peptide bonds in surrounding proteins, leading to progressive degeneration of desmosomal dense plaques, which are important cellular structures that participate in cell-to-cell adhesion

Degeneration results in detachment of tonofilaments that hold cells together, thereby leading to selective acantholysis (loss of cellular connections) and skin blistering when applied topically

Absorption

Plasma levels not detectable in 15 of 16 individuals following single application (average lesions treated 47.4)

1 of 16 had detectable plasma level of 3.391 ng/mL 2-hr post-dose

Previous
Next:

Administration

Topical Preparation

Instruct and train all healthcare professionals before preparation and administration

Use nitrile or vinyl gloves and eye protection during preparation and administration

See prescribing information for full instructions and diagrams

Use of applicator and break tool

  • Do not reuse the applicator
  • Applicator is for single treatment session only
  • Do not attempt to use a clogged applicator
  • Do not cut or modify applicator in any way; doing so could reduce dispensing control
  • Do not remove applicator cap before breaking glass ampule
  • If any damage or leaks are observed on applicator or break tool, discard applicator in a sharps container and handle in accordance with accepted medical practice and applicable law

Topical Administration

Applied topically by clinician

Not for oral, mucosal, or ophthalmic use

Clinician administration

  • See prescribing information for full instructions and diagrams
  • Use nitrile or vinyl gloves and eye protection during preparation and administration
  • Apply topically as a single application to cover each lesion; allow solution to completely dry (up to 5 minutes) before contacting healthy skin to avoid transference
  • Not to exceed 2 cantharidin applicators/single treatment session
  • Administer every 3 weeks as needed
  • Do not cover any treated lesions with bandages
  • If cantharidin contacts any unintended surface, including healthy skin, immediately remove by wiping with a cotton swab or gauze

Patient instructions

  • Avoid contact with the treatment area, including oral contact, after application
  • Do not apply near eyes
  • Remove with soap and water 24 hr after treatment
  • If severe blistering, severe pain, or other severe adverse reactions occur, remove with soap and water prior to 24 hours after treatment
  • Avoid other topical products on treated areas until 24 hr after treatment or until washing
  • Avoid fire, flame, or smoking near lesion(s) during treatment

Storage

Store at 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59-86ºF)

Protect from light

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.